The Keynote head and neck cancer clinical trials are studying an investigational drug, pembrolizumab, to see if it is safe and if it helps slow down or stop the growth of head and neck cancer. Head and neck cancers usually begin in the tissues and organs of the head and neck (eg, larynx, lips, mouth, nose, throat and salivary glands). Use of tobacco, excessive drinking and infection due to human papilloma virus (HPV) increase the risk of developing such cancers.
Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.
Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
You can also call our clinical trial information center at 1-888-577-8839 to learn more.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma||412||Head and Neck Neoplasms||Phase 3||Recruiting|
|Study of Pembrolizumab in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma or Locally Advanced Unresectable cSCC||629||Squamous Cell Carcinoma||Phase 2||Recruiting|
|Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma||689||Head and Neck Neoplasms||Phase 3||Recruiting|
|Pembrolizumab Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer||040||Head and Neck Squamous Cell Cancer||Phase 3||Active, not recruiting|
|A Study of Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck||048||
||Phase 3||Active, not recruiting|
|Study of MK-3475 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy||055||Head and Neck Squamous Cell Carcinoma||Phase 2||Active, not recruiting|
|Study of Pembrolizumab in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer||122||Nasopharyngeal Neoplasms||Phase 3||Active, not recruiting|
There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.